Catalent Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Catalent's earnings have been declining at an average annual rate of -51.3%, while the Pharmaceuticals industry saw earnings growing at 6.2% annually. Revenues have been growing at an average rate of 10.2% per year.

Anahtar bilgiler

-51.3%

Kazanç büyüme oranı

-51.0%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	12.4%
Gelir büyüme oranı	10.2%
Özkaynak getirisi	-28.9%
Net Marj	-23.8%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Catalent nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BMV:CTLT * Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	4,381	-1,043	935	0
31 Mar 24	4,135	-1,176	887	0
31 Dec 23	4,098	-1,302	853	0
30 Sep 23	4,223	-1,015	829	0
30 Jun 23	4,263	-256	839	0
31 Mar 23	4,495	21	840	0
31 Dec 22	4,731	389	866	0
30 Sep 22	4,799	399	867	0
30 Jun 22	4,802	483	844	0
31 Mar 22	4,703	485	803	0
31 Dec 21	4,483	561	768	0
30 Sep 21	4,177	544	706	0
30 Jun 21	3,998	529	687	0
31 Mar 21	3,757	494	658	0
31 Dec 20	3,465	289	623	0
30 Sep 20	3,275	250	598	0
30 Jun 20	3,094	173	577	0
31 Mar 20	2,872	104	562	1
31 Dec 19	2,729	124	554	2
30 Sep 19	2,631	138	535	3
30 Jun 19	2,518	132	512	0
31 Mar 19	2,478	149	489	4
31 Dec 18	2,488	136	475	5
30 Sep 18	2,471	65	466	5
30 Jun 18	2,463	84	459	6
31 Mar 18	2,395	63	430	7
31 Dec 17	2,300	70	413	7
30 Sep 17	2,177	109	396	7
30 Jun 17	2,075	110	396	7
31 Mar 17	1,991	106	373	7
31 Dec 16	1,896	91	365	7
30 Sep 16	1,867	104	362	8
30 Jun 16	1,848	112	351	8
31 Mar 16	1,826	207	346	10
31 Dec 15	1,835	228	333	10
30 Sep 15	1,836	244	327	11
30 Jun 15	1,831	212	325	12
31 Mar 15	1,840	86	315	14
31 Dec 14	1,847	62	320	15
30 Sep 14	1,832	-3	318	17
30 Jun 14	1,828	19	317	18
31 Mar 14	1,813	2	328	17
31 Dec 13	1,807	-20	326	16

Kaliteli Kazançlar: CTLT * is currently unprofitable.

Büyüyen Kar Marjı: CTLT * is currently unprofitable.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CTLT * is unprofitable, and losses have increased over the past 5 years at a rate of 51.3% per year.

Büyüme Hızlandırma: Unable to compare CTLT *'s earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: CTLT * is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).

Özkaynak Getirisi

Yüksek ROE: CTLT * has a negative Return on Equity (-28.94%), as it is currently unprofitable.

Catalent Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Insider recently sold Mex$4.4m worth of stock

President recently sold Mex$10.0m worth of stock

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

President recently sold Mex$1.6m worth of stock

Insufficient new directors

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

New minor risk - Earnings quality

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold Mex$1.3m worth of stock

Investor sentiment deteriorates as stock falls 36%

Investor sentiment improves as stock rises 50%

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Danaher Reportedly Expresses Takeover Interest in Catalent

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Insider recently sold Mex$796k worth of stock

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold Mex$3.2m worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Now 22% undervalued

Investor sentiment deteriorated over the past week

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Investor sentiment deteriorated over the past week

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Executive Chair of the Board recently sold Mex$80m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Catalent, Inc. Announces Board Changes

Insider recently sold Mex$251k worth of stock

Insider recently sold Mex$251k worth of stock

Insufficient new directors

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022